Comparative Acute Efficacy and Tolerability of OROS and Immediate Release Formulations of Methylphenidate in the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder

DSpace/Manakin Repository

Comparative Acute Efficacy and Tolerability of OROS and Immediate Release Formulations of Methylphenidate in the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder

Citable link to this page

 

 
Title: Comparative Acute Efficacy and Tolerability of OROS and Immediate Release Formulations of Methylphenidate in the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder
Author: Michel, Evan; Biederman, Joseph; Mick, Eric Owen; Surman, Craig B.H.; Hammerness, Paul Graves; Martin, Jessica; Doyle, Robert L.; Spencer, Thomas J.

Note: Order does not necessarily reflect citation order of authors.

Citation: Biederman, Joseph, Eric O. Mick, Craig Surman, Robert Doyle, Paul Hammerness, Evan Michel, Jessica Martin, and Thomas J. Spencer. 2007. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry 7: 49.
Full Text & Related Files:
Abstract: Background: The main aim of this study was to compare the safety and efficacy of IR MPH administered three times daily to those of once daily OROS-MPH. Methods: Subjects were outpatient adults satisfying full diagnostic criteria for DSM-IV ADHD between 19 and 60 years of age. Data from two independently conducted 6-week placebo controlled, randomized clinical trials of IR-MPH (tid) and of OROS-MPH were pooled to create three study groups: Placebo (N = 116), IR-MPH (tid) (N = 102) and OROS-MPH (N = 67). Results: Eight-five percent (N = 99) of placebo treated subjects, 77% (N = 79) of the IR-MPH (tid) treated subjects, and 82% (N = 55) of the OROS-MPH treated subjects completed the 6-week trial. Total daily doses at endpoint were 80.9 ± 31.9 mg, 74.8 ± 26.2 mg, and 95.4 ± 26.3 mg in the OROS-MPH, IR-MPH (tid), and placebo groups, respectively. At endpoint, 66% (N = 44) of subjects receiving OROS-MPH and 70% (N = 71) of subjects receiving IR-MPH (tid) were considered responders compared with 31% (N = 36) on placebo. Conclusion: Comparison of data from two similarly designed, large, randomized, placebo-controlled, trials, showed that equipotent daily doses of once daily OROS-MPH had similar efficacy to that of TID administered IR MPH. Trial Registration: The trial of OROS-MPH was registered at clinicaltrials.gov, number NCT00181571.
Published Version: doi:10.1186/1471-244X-7-49
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075491/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4874769
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters